New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 9, 2014
17:02 EDTREGN, SNYRegeneron, Sanofi announce positive results from Phase 2b study of Dupilumab
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis, a serious, chronic form of eczema. All doses of dupilumab met the primary endpoint of a greater improvement in Eczema Area and Severity Index scores from baseline compared to placebo. In addition, the companies also announced that four earlier clinical studies of dupilumab in moderate-to-severe atopic dermatitis were published in the New England Journal of Medicine. Dupilumab is an investigational monoclonal antibody that blocks signaling of IL-4 and IL-13, two cytokines that play a key role in the pathogenesis of moderate-to-severe atopic dermatitis.
News For REGN;SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
February 20, 2015
07:08 EDTSNY, REGNAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
February 19, 2015
16:50 EDTSNYSanofi appoints Olivier Brandicourt CEO
Subscribe for More Information
16:28 EDTREGNOn The Fly: Closing Wrap
Subscribe for More Information
15:58 EDTREGNRegeneron downgraded to Neutral from Buy at Roth Capital
Subscribe for More Information
10:00 EDTREGNRegeneron Praluent launch costs a concern, says Piper Jaffray
Subscribe for More Information
09:59 EDTSNYOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Altisource Residential (RESI) upgraded to Neutral from Sell at Compass Point... Angie's List (ANGI) upgraded to Overweight from Equal-Weight at First Analysis... Barrick Gold (ABX) upgraded to Buy from Hold at TD Securities... British Land (BTLCY) upgraded to Buy from Hold at Societe Generale... Coach (COH) upgraded to Buy from Hold at Topeka... Fiat Chrysler (FCAU) upgraded to Outperform from Neutral at Exane BNP Paribas... Garmin (GRMN) upgraded at BofA/Merrill... Hologic (HOLX) upgraded to Buy from Hold at Canaccord... Iberdrola (IBDRY) upgraded to Neutral from Underweight at HSBC... KPN (KKPNY) upgraded to Neutral from Underperform at Exane BNP Paribas... Monster Worldwide (MWW) upgraded at Evercore ISI... Pharmacyclics (PCYC) upgraded to Buy from Neutral at Nomura... RPC, Inc. (RES) upgraded to Equal Weight from Underweight at Morgan Stanley... Sanofi (SNY) upgraded to Buy from Neutral at BofA/Merrill... Sasol (SSL) upgraded to Neutral from Underweight at HSBC... Tractor Supply (TSCO) upgraded at Oppenheimer... Valero (VLO) upgraded to Buy from Hold at Deutsche Bank... Weingarten Realty (WRI) upgraded to Neutral from Sell at UBS... Werner (WERN) upgraded on improving freight fundamentals at RBC Capital... diaDexus (DDXS) upgraded to Buy from Neutral at Ladenburg,
09:01 EDTREGNData to accelerate growth of Regeneron's Eylea, says Bernstein
Subscribe for More Information
07:28 EDTREGNRegeneron data better than expected, says RBC Capital
RBC Capital believes that Protocol-T results for Regneron's (REGN) Eylea were better than expected. The firm says that Eylea improved the vision of all patients more than Roche's treatments,and was much better than Roche's drugs in treating patients with moderate or worse vision loss. The firm keeps a $490 price target and Outperform rating on Regeneron.
06:56 EDTREGNData support Regeneron drug over competition, says Deutsche Bank
Subscribe for More Information
06:45 EDTREGNStudy shows Roche's treatments equal to Eylea in most cases, NY Times says
Subscribe for More Information
06:21 EDTSNYSanofi upgraded to Buy from Neutral at BofA/Merrill
05:31 EDTSNYSanofi upgraded to Buy from Neutral at BofA/Merrill
February 18, 2015
17:23 EDTREGNRegeneron reports positive results for Eylea injection in diabetic macular edema
Subscribe for More Information
03:20 EDTREGNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
February 17, 2015
11:38 EDTSNYGenzyme reports publication of ENGAGE registration study results
Subscribe for More Information
10:01 EDTREGNCVS says PCSK9 inhibitors could cost system $150B annually
Subscribe for More Information
10:00 EDTREGNOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Box, Inc. (BOX) initiated with a Hold at Canaccord... Euronav NV (EURN) initiated with an Overweight at Morgan Stanley... GoPro (GPRO) initiated with an Outperform at Northland... M/A-COM (MTSI) initiated with a Neutral at BofA/Merrill... Macy's (M) initiated with an Underweight at Barclays... NetSuite (N) initiated with an Underperform at Exane BNP Paribas... Omega Healthcare (OHI) initiated with a Neutral at BofA/Merrill... Pandora (P) initiated with a Neutral at Macquarie... Pattern Energy (PEGI) coverage resumed with an Outperform at BMO Capital... Regeneron (REGN) initiated with an Outperform at Bernstein... Trovagene (TROV) initiated with an Overweight at Piper Jaffray... Vista Outdoor (VSTO) initiated with a Market Perform at Cowen.
06:35 EDTREGNRegeneron initiated with an Outperform at Bernstein
Target $475.
February 12, 2015
16:20 EDTSNYGenzyme announces data from Phase 1b study for Niemann-Pick Type B
Subscribe for More Information
08:52 EDTSNYSanofi's Genzyme reports Phase 3 results for Cerdelga
Genzyme, a Sanofi company, reported extension study data from its Phase 3 ENGAGE and ENCORE studies of Cerdelga, or eliglustat, a first-line oral therapy approved by the FDA and the European Commission for the treatment of certain adults with Gaucher disease type 1. Both extension studies demonstrated continued stability and/or improvements across established end points and published therapeutic treatment goals. ENGAGE is a phase 3, randomized, double-blind, placebo-controlled, multi-center tudy to investigate the efficacy and safety of eliglustat in adults with gaucher disease type 1. After 18 months, in the primary analysis period, improvements were seen across the following endpoints after 9 months on cerdelga: spleen size, platelet count, hemoglobin concentration, and liver volume. In the 9 month extension phase, patients who switched from placebo to eliglustat showed improvements similar to the eliglustat-treated patients during the primary analysis while the eliglustat-treated patients continued to show improvements during the 9 month extension period. There were no treatment-related discontinuations. ENCORE is a phase 3, randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in gaucher disease type 1 patients stabilized on enzyme replacement therapy. After 24-months, the study, which met the primary analysis criteria for non-inferiority to imiglucerase, had a composite endpoint of each of the following parameters: spleen volume, hemoglobin concentration, platelet counts, and liver volume at 12 months. During the 12-month extension period, the patients who crossed over to eliglustat treatment from imiglucerase remained stable. Patients treated with eliglustat for 24 months also maintained stability of clinical parameters during the extension period. The most common adverse reactions -- ≥10% -- in the primary analysis periods of ENGAGE and ENCORE were fatigue, headache, nausea, diarrhea, back pain, pain in extremities, and upper abdominal pain. In both extension studies the majority of adverse reactions with Cerdelga were mild and transient, and consistent with those in the primary analysis periods. Most patients in both of the Phase 3 studies continue to receive Cerdelga in longer term extension periods. The majority of patients are now in their 4th or 5th year of treatment.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use